A new monoclonal antibody which targets interleukin-23 (IL-23) is now available in Malaysia. Guselkumab (TREMFYA™, Janssen Pharmaceutical Companies of Johnson & Johnson) is a subcutaneously injected agent that blocks the body’s inflammatory pathway, namely, IL-23.
The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of nonsmall cell lung cancer (NSCLC) commonly triggers cutaneous side effects, which often leads to drug reductions or discontinuation, reports a new study at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).
Continuous treatment with baricitinib maintains clear or almost clear skin in patients with moderate-to-severe atopic dermatitis (AD) over 68 weeks, according to long-term results from the BREEZE-AD3 study presented during EADV 2020.
The investigational JAK1* selective inhibitor abrocitinib was effective and well-tolerated in adolescents and adults with moderate-to-severe atopic dermatitis (AD), the phase III JADE MONO-2 trial has shown.
The PD-1 inhibitor nivolumab continues to yield sustained recurrence-free survival (RFS) benefit over ipilimumab with better tolerability at 4 years in the adjuvant setting for patients with resected stage IIIB–C or IV melanoma, according to the CheckMate 238 trial presented at ESMO 2020.
Cetirizine drip for treating acute urticaria is as effective as intravenous diphenhydramine, with the added benefits of less sedation, fewer adverse events, shorter treatment time, and lower rates of revisit to treatment centre, according to the results of a phase III study.
Treatment with clascoterone cream 1% results in a favourable safety profile, with a low frequency of treatment-emergent adverse events (TEAEs) over 9 months, in patients with acne vulgaris, results of a recent study have shown.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).